Next Article in Journal
Usefulness of the Waist Circumference-to-Height Ratio in Screening for Obesity and Metabolic Syndrome among Korean Children and Adolescents: Korea National Health and Nutrition Examination Survey, 2010–2014
Previous Article in Journal
Iodine and Selenium Intakes of Postmenopausal Women in New Zealand

Effects of Resveratrol Supplementation on  Methotrexate Chemotherapy‐Induced Bone Loss

Sansom Institute for Health Research, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide SA 5001, Australia
Institute of Orthopaedics, Lanzhou General Hospital, Lanzhou Command of People’s Liberation Army, Lanzhou 730050, China
Clinical Nutrition Research Centre, University of Newcastle, Callaghan NSW 2308, Australia
Author to whom correspondence should be addressed.
Nutrients 2017, 9(3), 255;
Received: 16 February 2017 / Accepted: 8 March 2017 / Published: 9 March 2017
Intensive cancer chemotherapy is known to cause bone defects, which currently lack treatments. This study investigated the effects of polyphenol resveratrol (RES) in preventing bone defects in rats caused by methotrexate (MTX), a commonly used antimetabolite in childhood oncology. Young rats received five daily MTX injections at 0.75 mg/kg/day. RES was orally gavaged daily for seven days prior to, and during, five‐day MTX administration. MTX reduced growth plate thickness, primary spongiosa height, trabecular bone volume, increased marrow adipocyte density, and increased mRNA expression of the osteogenic, adipogenic, and osteoclastogenic factors in the tibial bone. RES at 10 mg/kg was found not to affect bone health in normal rats, but to aggravate the bone damage in MTX‐treated rats. However, RES supplementation at 1 mg/kg preserved the growth plate, primary spongiosa, bone volume, and lowered the adipocyte density. It maintained expression of genes involved in osteogenesis and decreased expression of adipogenic and osteoclastogenic factors. RES suppressed osteoclast formation ex vivo of bone marrow cells from the treated rats. These data suggest that MTX can enhance osteoclast and adipocyte formation and cause bone loss, and that RES supplementation at 1 mg/kg may potentially prevent these bone defects. View Full-Text
Keywords: resveratrol; cancer chemotherapy; methotrexate; bone loss; bone marrow adiposity;  bone growth arrest; growth plate; osteoclasts; osteoblasts; adipocytes resveratrol; cancer chemotherapy; methotrexate; bone loss; bone marrow adiposity;  bone growth arrest; growth plate; osteoclasts; osteoblasts; adipocytes
Show Figures

Figure 1

MDPI and ACS Style

Lee, A.M.C.; Shandala, T.; Soo, P.P.; Su, Y.; King, T.J.; Chen, K.; Howe, P.R.; Xian, C.J. Effects of Resveratrol Supplementation on  Methotrexate Chemotherapy‐Induced Bone Loss. Nutrients 2017, 9, 255.

AMA Style

Lee AMC, Shandala T, Soo PP, Su Y, King TJ, Chen K, Howe PR, Xian CJ. Effects of Resveratrol Supplementation on  Methotrexate Chemotherapy‐Induced Bone Loss. Nutrients. 2017; 9(3):255.

Chicago/Turabian Style

Lee, Alice M.C., Tetyana Shandala, Pei P. Soo, Yu‐Wen Su, Tristan J. King, Ke‐Ming Chen, Peter R. Howe, and Cory J. Xian 2017. "Effects of Resveratrol Supplementation on  Methotrexate Chemotherapy‐Induced Bone Loss" Nutrients 9, no. 3: 255.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop